I don't see what the issue is. The half/full subgroup was too small (and only 18-55yo) for MHRA approval. But the subgroup that was approved (evidently) was not. Why does one subgroup not fitting the criteria, but another subgroup fitting it, and therefore able to be accepted, a bad thing? A perfectly acceptable method has been found. There is nothing wrong with have a method that passes regulatory approval, people seem to be implying figures have been fudged. The figures have been released if you want to look at them, it's weird you'd take a lack of understanding the evidence as a reason to not trust medical professionals.
This was 12,000 people (6,000 in each arm) who received their second dose between 4-26 weeks after their first dose. Up until either a) the day they got the second dose or b) 12 weeks after their first dose, there had been 30 infections in the vaccine arm, and 101 in the control arm = so around 70 infections prevented by one dose of the vaccine for every 100 that occur. So 70% protection.
Data here:
https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca